导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.62% | 1357/4773 |
| 近一周 | -2.51% | 2409/5462 |
| 近一月 | -4.93% | 2872/5421 |
| 近一季 | -8.50% | 2823/5209 |
| 近半年 | -5.68% | 2929/4920 |
| 近一年 | 9.26% | 1107/4366 |
| 近两年 | 73.24% | 913/2954 |
| 近三年 | 39.10% | 743/2253 |
| 成立以来 | 94.73% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.01% 1098/4961 |
19.00% 1330/5312 |
- - |
- - |
| 2025 | 32.08% 1199/4813 |
2.25% 1423/3635 |
2.08% 1883/4076 |
24.54% 1451/4524 |
1.61% 1305/4813 |
| 2024 | 6.36% 1766/3463 |
-2.92% 1452/2808 |
-4.98% 1606/3014 |
15.76% 1632/3129 |
-0.40% 1405/3463 |
| 2023 | -5.02% 709/2656 |
7.69% 534/2280 |
-3.74% 885/2385 |
-4.29% 1106/2515 |
-4.27% 941/2655 |
| 2022 | -16.76% 514/2207 |
-13.18% 711/1919 |
3.87% 1081/2016 |
-10.19% 361/2113 |
2.78% 837/2208 |
| 2021 | 19.58% 189/1822 |
-0.99% 415/1255 |
10.37% 467/1330 |
5.48% 271/1466 |
3.73% 397/1822 |
| 2020 | 28.36% 562/1250 |
-2.95% 282/1028 |
17.20% 385/1067 |
8.37% 718/1164 |
4.14% 866/1184 |
| 2019 | - - |
- - |
-3.27% 375/788 |
0.63% 498/850 |
6.73% 558/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达中证500ETF联接发起式A VS. 长安沪深300非周期A(740101) |